ArticleScience China. Life sciences2015
Angiotensin II receptor blocker as a novel therapy in acute lung injury induced by avian influenza A H5N1 virus infection in mouse.
Article in Science China. Life sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 42 citations in OpenAlex.
- Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: Insights from the BRACE CORONA trial.American heart journal · 2022Trial
- The key mechanisms of multi-system responses triggered by central nervous system damage in hand, foot, and mouth disease severity.Infectious medicine · 2024Review
- Impact of Angiotensin Receptor Blockers Use on In-Hospital Mortality in Community-Acquired Pneumonia Patients with Hypertension.Kidney diseases (Basel, Switzerland) · 2023Article
- Potential of angiotensin II receptor blocker telmisartan in reducing mortality among hospitalized patients with COVID-19 compared with recommended drugs.Cell discovery · 2022Article
- Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies.Signal transduction and targeted therapy · 2021Review
- Human gene polymorphisms and their possible impact on the clinical outcome of SARS-CoV-2 infection.Archives of virology · 2021Review
- Discontinuation of Antihypertensive Medications on the Outcome of Hospitalized Patients With Severe Acute Respiratory Syndrome-Coronavirus 2.Hypertension (Dallas, Tex. : 1979) · 2021Observational
- A pharmacological framework for integrating treating the host, drug repurposing and the damage response framework in COVID-19.British journal of clinical pharmacology · 2021Review
- Angiotensin Converting Enzyme-2 (ACE-2) role in disease and future in research.Journal of lung, pulmonary & respiratory research · 2021Article
- Safety of ACE-I and ARB medications in COVID-19: A retrospective cohort study of inpatients and outpatients in California.Journal of clinical and translational science · 2021Article
- Controversial Roles of the Renin Angiotensin System and Its Modulators During the COVID-19 Pandemic.Frontiers in physiology · 2021Review
- Article
- A hypothesis for pathobiology and treatment of COVID-19: The centrality of ACE1/ACE2 imbalance.British journal of pharmacology · 2020Review
- Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients.Cell discovery · 2020Article
- Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.Frontiers of medicine · 2020Article
- Role of the renin-angiotensin system in the development of severe COVID-19 in hypertensive patients.American journal of physiology. Lung cellular and molecular physiology · 2020Review
- Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19.Critical care (London, England) · 2020Review
- Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation.Aging cell · 2020Article
- Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review.The European respiratory journal · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.